Opinion|Videos|July 18, 2024
Next Steps in the Development of Axatilimab
Corey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- While axatilimab targets a novel pathway in cGVHD, what other unmet needs persist in managing this condition?
- What are the key challenges in improving overall outcomes and quality of life for patients with cGVHD?
- Are there any promising emerging therapies, combination approaches, or ongoing trials that could complement axatilimab's role in the cGVHD treatment landscape?
- Are there any promising emerging therapies, combination approaches, or ongoing trials that could complement axatilimab's role in the cGVHD treatment landscape?
- What are the key challenges in improving overall outcomes and quality of life for patients with cGVHD?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5